Trial · NCT04063124
Senolytic Therapy to Modulate Progression of Alzheimer's Disease
NCT04063124, Phase 1, Phase 2, Completed, The University of Texas Health Science Center at San Antonio; results first posted 2023-03-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Senolytic Therapy to Modulate Progression of Alzheimer's Disease. Trials, record NCT04063124. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04063124
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Senolytic Therapy to Modulate Progression of Alzheimer's Disease
- NCT number
- NCT04063124
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Conditions
- Alzheimer Disease
- Interventions
- Dasatinib + Quercetin
- First posted
- 2019-08-21
- Last updated
- 2023-03-06
- Results first posted
- 2023-03-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Brain Penetrance of Dasatinib (D) | Change from 0 to 12 weeks | Cerebrospinal Fluid (CSF) collected by lumbar puncture before and after 12 weeks of treatment to determine levels of drug that reach the central nervous system will be measured by high performance liquid chromatography/mass spectrometry (HPLC/MS) |
| Primary | Brain Penetrance of Quercetin (Q) | Change from 0 to 12 weeks | CSF collected by lumbar puncture before and after 12 weeks of treatment to determine levels of drug that reach the central nervous system using HPLC/MS |
| Secondary | Alzheimer's Disease Marker - CSF Tau | Change from 0 to 12 weeks | Cerebrospinal Fluid collected by lumbar puncture analyzed for level of tau proteins present in CSF |
| Secondary | Alzheimer's Disease Marker - CSF Amyloid Beta | Change from 0 to 12 weeks | Cerebrospinal Fluid collected by lumbar puncture analyzed for level of amyloid beta proteins present in CSF |
| Secondary | Senescence Marker IL-6 in CSF | Change from 0 to 12 weeks | Laboratory measure of level of IL-6 found in CSF collected pre and post treatment |
| Secondary | Senescence Marker P16 in CSF | Change from 0 to 12 weeks | Laboratory measure of level of P16 found in CSF collected pre and post treatment |
| Secondary | Electronic Gait Mapping Under Single and Dual-task Conditions | Change from 0 to 12 weeks | Participants walk on a pressure-sensitive walkway to capture data on gait speed |
| Secondary | Montreal Cognitive Assessment (MoCA) | Change from 0 to 12 weeks | A test which scores the participant with score ranges between 0 and 30. A score of 26 or over is considered normal. Individuals with mild cognitive impairment score lower and individuals with Alzheimer's disease score even lower. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Brain Penetrance of Dasatinib (D) | Change from 0 to 12 weeks | tandem mass spectrometry | ng/ml | MEAN |
| PRIMARY | Brain Penetrance of Quercetin (Q) | Change from 0 to 12 weeks | tandem mass spectrometry | ng/ml | MEAN |
| SECONDARY | Alzheimer's Disease Marker - CSF Tau | Change from 0 to 12 weeks | total tau assessed by Simoa HD-X analyzer | pg/ml | MEAN |
| SECONDARY | Alzheimer's Disease Marker - CSF Amyloid Beta | Change from 0 to 12 weeks | Abeta 42 assessed using Simoa HD-X Analyzer | pg/ml | MEAN |
| SECONDARY | Senescence Marker IL-6 in CSF | Change from 0 to 12 weeks | Assessed using Meso-Scale Discovery platform | pg/ml | MEAN |
| SECONDARY | Senescence Marker P16 in CSF | Change from 0 to 12 weeks | Data were not collected for this outcome measure | ||
| SECONDARY | Electronic Gait Mapping Under Single and Dual-task Conditions | Change from 0 to 12 weeks | Data were not collected for this outcome measure | ||
| SECONDARY | Montreal Cognitive Assessment (MoCA) | Change from 0 to 12 weeks | Change in points out of 30 | points | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Brain Penetrance of Dasatinib (D) | Intermittent D+Q | 0.27 | Standard Deviation 0.19 | ng/ml | |
| Brain Penetrance of Quercetin (Q) | Intermittent D+Q | 0 | Standard Deviation 0 | ng/ml | |
| Alzheimer's Disease Marker - CSF Tau | Intermittent D+Q | -21 | Standard Deviation 35 | pg/ml | |
| Alzheimer's Disease Marker - CSF Amyloid Beta | Intermittent D+Q | 78 | Standard Deviation 75 | pg/ml | |
| Senescence Marker IL-6 in CSF | Intermittent D+Q | 0.37 | Standard Deviation 0.20 | pg/ml | |
| Montreal Cognitive Assessment (MoCA) | Intermittent D+Q | -0.20 | Standard Deviation 2.28 | points |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intermittent D+Q | 5 | |
| Overall Study | COMPLETED | Intermittent D+Q | 5 | |
| Overall Study | NOT COMPLETED | Intermittent D+Q | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fall | General disorders | Intermittent D+Q | 1 | 5 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Intermittent D+Q | 1 | 5 | 1 |
| other | Urinary tract infection | Renal and urinary disorders | Intermittent D+Q | 2 | 5 | 2 |
| other | Hypoglycemia | Endocrine disorders | Intermittent D+Q | 1 | 5 | 1 |
| other | Hematuria | Renal and urinary disorders | Intermittent D+Q | 1 | 5 | 1 |
| other | Emesis | Gastrointestinal disorders | Intermittent D+Q | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intermittent D+Q | 0 | 5 |
| Total, other adverse events | Intermittent D+Q | 4 | 5 |
| Total, serious adverse events | Intermittent D+Q | 0 | 5 |
Source ClinicalTrials.gov
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04063124
GET https://conductscience.org/api/trials/v1/NCT04063124/registered